President Trump’s 100% tariff on branded and patented drugs spares Indian generics for now, easing immediate concerns. Analysts expect a rebound as clarity grows. “Only around 3% of India’s exports will get impacted, as the majority are generic formulations,” said Suddhir Jain, Founder, Bionova Group, noting the move is unlikely to dent India’s pharma trade significantly.